Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Endosc. Jul 16, 2022; 14(7): 416-423
Published online Jul 16, 2022. doi: 10.4253/wjge.v14.i7.416
Table 1 Baseline characteristics of patient population on anti-angiogenic agents
Characteristics
Anti-angiogenic agents (n = 59)
Age64.9
Female34 (57.62%)
Race
Caucasian32 (54.2%)
African American24 (40.7%)
Hispanic3 (5.1%)
Malignancy sites
Colorectal cancer12 (20.3%)
Hepatocellular cancer7 (11.9%)
Ovarian cancer6 (10.2%)
Lung6 (10.2%)
CML/AML5 8.5%)
Renal cell cancer4 (6.8%)
Oropharyngeal cancer3 (5.1%)
Uterine2 (3.4%)
Pancreas2 (3.4%)
Gastric cancer2 (3.4%)
Fibrosarcoma2 (3.4%)
Peritoneal carcinomatosis2 (3.4%)
Cervical cancer2 (3.4%)
Fallopian tube1 (1.7%)
Breast cancer1 (1.7%)
Other2 (3.4%)
HHT/Hereditary eosinophilia
Stage of malignancy
Unstageable9 (13.6%)
Stage I1 (1.7%)
Stage II3 (5.1%)
Stage III11 (18.6%)
Stage IV35 (59.3)